ReviewInvestigational new drugs1999
Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.
Review in Investigational new drugs, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 254 citations in OpenAlex.
- [Value of targeted therapy for penile cancer].Der Urologe. Ausg. A · 2008Pooled it
- Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2012Trial
- Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer.Bosnian journal of basic medical sciences · 2008Trial
- Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).British journal of cancer · 2004Trial
- Review
- Synthesis of Pyrido[2,3-d]Azolopyrimidinones: Design and Epidermal Growth Factor Receptor-Targeted Molecular Docking Toward Novel Anticancer Leads.ChemistryOpen · 2026Article
- Expression of EGFR and p16 in Squamous Cell Carcinoma of External Auditory Canal.The Kobe journal of medical sciences · 2024Article
- Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial.Frontiers in oncology · 2024Article
- Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-Journal of enzyme inhibition and medicinal chemistry · 2023Article
- EGFR and MMP-9 are associated with neointimal hyperplasia in systemic-to-pulmonary shunts in children with complex cyanotic heart disease.Mammalian genome : official journal of the International Mammalian Genome Society · 2023Article
- Ultraviolet Radiation Exposure and its Impacts on Cutaneous Phosphorylation Signaling in Carcinogenesis: Focusing on Protein Tyrosine PhosphatasesPhotochemistry and photobiology · 2023Review
- Computer-Assisted Drug Discovery of a Novel Theobromine Derivative as an EGFR Protein-Targeted Apoptosis Inducer.Evolutionary bioinformatics online · 2023Article
- Design, synthesis and molecular docking of new fused 1Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Tailoring the clinical management of colorectal cancer byFrontiers in oncology · 2022Review
- Article
- Comparison of gefitinib-induced skin adverse reactions (SAR) in C57BL/6 and FVB/N mice.Toxicology research · 2021Article
- Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature.Journal of ovarian research · 2021Review
- Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them.The Journal of biological chemistry · 2020Review
- From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.Anti-cancer agents in medicinal chemistry · 2018Review
- Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment.OncoTargets and therapy · 2018Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidermal growth factor receptor (EGFR), a growth factor receptor involved in the regulation of cellular differentiation and proliferation, is highly expressed by many tumor cells. In light of a relationship between overexpression of EGFR and clinically aggressive malignant disease, EGFR has emerged as a promising target for cancer therapy. In recent years, several molecular strategies have been explored to modulate either the EGFR itself, or the downstream signal beyond the cell surface receptor. One of the most promising current strategies involves the use of anti-EGFR monoclonal antibodies (mAbs), either alone or in combination with conventional cytotoxic modalities such as chemotherapy or radiotherapy. This review focuses primarily on recent progress in the development of anti-EGFR mAbs, and examines their potential in the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.